
Clinically Significant Vision Gains (≥15 letters) Across 3 Robust Clinical
Trials in MEfRVO
Over half of patients with Macular Edema following Retinal Vein Occlusion achieved substantial improvements
in visual acuity within 6 months
Proportion of patients who gained ≥15 ETDRS letters at Month 6 from baseline vs control1-4,*
VIBRANT Study Design
Randomized, multicenter, double-masked, controlled study in which patients with MEfBRVO (N=181; age range: 42-94 years, with a mean of 65 years) were randomized to receive: 1) EYLEA 2 mg Q4 or 2) laser photocoagulation administered
at baseline and subsequently as needed
(control group).1
The primary efficacy endpoint was the proportion of patients who gained ≥15 letters in BCVA at Week 24 compared with baseline.1
COPERNICUS and GALILEO
Study Designs
Randomized, multicenter, double-masked, sham-controlled studies in patients with MEfCRVO (N=358; age range: 22-89 years, with a mean of 64 years). Patients were assigned in a 3:2 ratio to either: 1) EYLEA 2 mg Q4 for the first 6 months or 2) sham injections (control) Q4 for a total of 6 injections.1
In both studies, the primary efficacy endpoint was the proportion of patients who gained ≥15 letters in BCVA at Week 24 compared with baseline.1
BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; Q4, every 4 weeks.
Rapid, Sustained Improvements in Visual Acuity
EYLEA led to mean gains of 17 or more ETDRS letters at Month 6 in all 3 pivotal MEfRVO trials
Mean change in BCVA (ETDRS letters) through Month 6 from baseline1,5,*






BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; Q4, every 4 weeks.
First-line Efficacy Across a Wide Range of Patient Types in MEfRVO1
Patients achieved clinically significant vision gains regardless of having better or worse than 20/200 vision at baseline
Proportion of patients who gained ≥15 ETDRS letters at Month 6 from baseline by baseline BCVA (prespecified subgroup analysis)5,*


The results of this prespecified subgroup analysis require cautious interpretation and could represent chance findings, as a multiplicity adjustment has not been applied.
Treatment effects in evaluable subgroups in each study were, in general, consistent with the results in the overall populations.1
EYLEA demonstrated clinically significant vision gains regardless of baseline retinal perfusion
Proportion of patients who gained ≥15 ETDRS letters at Month 6 from baseline by perfusion status (prespecified subgroup analysis)5,*


The results of this prespecified subgroup analysis require cautious interpretation and could represent chance findings, as a multiplicity adjustment has not been applied.
Treatment effects in evaluable subgroups in each study were, in general, consistent with the results in the overall populations.1
BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; Q4, every 4 weeks.
Earlier Treatment With EYLEA Led to Increased Vision Gains in MEfCRVO
A higher proportion of patients achieved significant vision gains when treated within 2 months of diagnosis
Proportion of patients who gained ≥15 ETDRS letters at Month 6 from baseline by time to treatment initiation (protocol-specified subgroup analysis)5,*


ETDRS, Early Treatment Diabetic Retinopathy Study; Q4, every 4 weeks.

Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more.
